The current U.S. Defense Secretary, Donald Rumsfeld, has a history of dabbling in health chicanery.  At G.D. Searle he facilitated FDA approval for Nutrasweet. More recently he served as head of Gilead Sciences, the company that developed, then leased the rights to Roche Pharmaceuticals, to the worthless flu drug Tamiflu.

When I wrote about Rumsfeld in December it was unclear just how much stock he held and how much it was worth. Now we know.

So far, Rumsfeld has made a "killing" (pun intended) on the stock market, and the estimations that set the current value of his remaining stock at $25 million are likely to be well under their actual value, considering Roche's decision to expand Tamiflu production.

Sadly, current ethics rules in American government don't prevent Rumsfeld from owning stocks or making money from health-harming substances like Tamiflu or aspartame, even though he likely has some say in their purchase or approval by the government, and therefore their stock value.

No surprise, since drug companies use their largesse to buy favors and influence from Congress and the White House.
                                                        ======================